teknova

teknova

Supplies custom molecular biology media

Overview

Teknova provides custom molecular biology media and related products for the life sciences sector, including buffers, reagents, pre-poured agar plates, and both dry and liquid culture media. By offering tailored media solutions, the company helps biotechnology, pharmaceutical, and academic researchers save time and money, with short lead times and competitive pricing. Its product range includes high-yield E. coli growth media, induction media kits, and protein extraction kits, enabling customers to outsource media preparation and focus on their core experiments. Teknova differentiates itself through customization and fast, cost-effective supply of ready-to-use media and solutions, serving as a reliable source for essential lab materials. The company's goal is to support researchers by providing high-quality, customized media that streamline experimental workflows and reduce operational costs, potentially helping clients save up to around $1 million annually.

About teknova

Simplify's Rating
Why teknova is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & Manufacturing

Biotechnology

Education

Healthcare

Company Size

51-200

Company Stage

IPO

Headquarters

Hollister, California

Founded

1996

Get referred to teknova

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Teknova raised 2026 revenue guidance to $45 million-$47 million after 18% Q2 growth.
  • Free cash outflow fell to $0.6 million in Q2 2026, near breakeven.
  • Clinical customers grew 25% in 2025, and one commercial therapy starts soon.

What critics are saying

  • Teknova carried $13.2 million borrowings against $17.4 million cash on June 30, 2026.
  • Clinical Solutions growth trails management's promise; cell and gene therapy demand stayed soft in Q2 2026.
  • If commercial therapy ramp stalls by 2027, Teknova's cash burn revives and refinancing risk returns.

What makes teknova unique

  • Teknova's Build-Tek launched August 5, 2026, speeding custom reagent quoting in minutes.
  • Teknova supports over 70 clinical-stage therapies, with commercialization multiplying customer spend.
  • Teknova's small-batch GMP platform and fast turnaround serve RUO-to-commercial workflows.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$132.3M

Above

Industry Average

Funded Over

3 Rounds

Private Placement Non VC funding comparison data is currently unavailable. We're working to provide this information soon!
Private Placement Non VC Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Employee Stock Purchase Plan

Wellness Program

Paid Holidays

Paid Vacation

Paid Sick Leave

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jun 16th, 2026
Teknova launches customised Bioz Content Hub for scientific publication data

Bioz, a platform extracting insights from scientific publications, has expanded its collaboration with Teknova, a manufacturer of critical reagents for therapy and vaccine development. Teknova has implemented a fully customised Bioz Content Hub, creating a centralised destination for publication data across its product portfolio. The Content Hub consolidates peer-reviewed publications into a searchable environment, enabling researchers to explore real-world applications of Teknova's products. The platform integrates directly within Teknova's website, matching its design and navigation whilst allowing users to browse and filter publication data seamlessly. The integration eliminates manual publication tracking whilst ensuring citation data remains continuously updated. Teknova joins other life sciences suppliers using Bioz's solutions to enhance user engagement and strengthen scientific transparency through evidence-based product validation.

Access Newswire
Jun 16th, 2026
Teknova expands digital publication experience with Bioz Content Hub integration.

Teknova expands digital publication experience with Bioz Content Hub integration. Tuesday, 16 June 2026 04:00 AM Partnerships. PALO ALTO, CA / ACCESS Newswire / June 16, 2026 / Bioz, Inc., an innovative platform focused on extracting and syndicating insights from scientific publications, announced its continued collaboration with Teknova, a leading manufacturer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Building on a long-standing collaboration, Teknova has expanded its use of Bioz Badges by implementing a fully customized Bioz Content Hub, creating a centralized, standalone destination for publication data across its product portfolio. As the volume of scientific literature continues to grow, suppliers face increasing challenges in organizing and presenting validated evidence in a way that is both scalable and user-friendly. Teknova's Content Hub addresses this by consolidating peer-reviewed publications into a dedicated, searchable environment, enabling researchers to easily explore how Teknova's customers use the company's products across a wide range of applications. "Long-term "collaborators" or "users" like Teknova understand the importance of not only surfacing publication data, but doing so in a way that aligns with their digital strategy and user experience," said Dr. Karin Lachmi, Co-Founder and Chief Revenue Officer at Bioz. "By expanding from Bioz Badges to a fully customized Content Hub, Teknova has created a highly intuitive and scalable solution that strengthens scientific transparency while enhancing engagement." The Teknova Content Hub is fully tailored to match the look, feel, and navigation of their website, ensuring a seamless user experience. Rather than directing users to external or static resources, the Bioz Content Hub integrates directly within Teknova's digital ecosystem, allowing researchers to browse, filter, and interact with publication data in a way that feels native to the site. Users can easily navigate from publications to associated product webpages, creating a streamlined path from evaluation to procurement. "The nature of our work with Bioz has evolved alongside our digital strategy," said Christa Plon, Marketing Operations Specialist at Teknova. "The launch of our Bioz Content Hub allows us to present publication data in a way that is not only comprehensive, but also highly aligned with our brand and user experience. The level of UI customization ensures that researchers can engage with our content intuitively while exploring real-world applications of our products." Jennifer Henry, Senior Vice President of Marketing at Teknova, added, "Having a centralized publication resource has significantly improved how we organize and present scientific validation across our vast product portfolio. The ability to seamlessly connect publications to each individual product makes it easier for customers to find relevant data and better understand the practical and real-world usage of our products in the development of next-generation therapeutics and diagnostics..." In adding a standalone Bioz Content Hub, Teknova is reinforcing its commitment to evidence-driven communication, user-centric design, and scalable digital infrastructure. The integration eliminates the need for manual publication tracking while ensuring that citation data remains continuously updated, accessible, and actionable for researchers. About Bioz Bioz is the world's most advanced citation platform for scientific research, offering evidence-based product ratings and recommendations to guide scientists toward the most validated products for their discoveries. Bioz's solutions for suppliers include Bioz Badges and Content Hubs, web-based widgets that enhance user engagement and increase sales conversion. About Teknova Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. Teknova offers fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Their fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova's modular manufacturing platform was designed by their team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies. Helpful Links

Yahoo Finance
May 9th, 2026
Alpha Teknova posts Q1 results 9.5% ahead of forecasts, analysts maintain $9.00 price target

Alpha Teknova has reported first-quarter results that beat analyst expectations, with revenues of $11 million arriving 9.5% higher than forecasts. Statutory losses came in at $0.08 per share, also 9.5% better than expected. Following the results, six analysts maintained their consensus revenue forecast of $43.3 million for 2026, representing a 3.6% increase on the past 12 months. Loss estimates remained unchanged at $0.35 per share. The consensus price target holds at $9.00, with individual targets ranging from $7.00 to $12.00. Analysts expect Alpha Teknova's revenue growth to accelerate to 4.8% annually through 2026, up from historical growth of 0.9% over the past five years. However, this remains below the 6.5% industry average growth forecast.

Yahoo Finance
Mar 22nd, 2026
Alpha Teknova targets EBITDA profit by 2027 as clinical solutions grow 25%

Alpha Teknova reported fiscal 2025 revenue of $40.5 million and a $7 million adjusted EBITDA loss, targeting EBITDA profitability by end of 2027 once it reaches an annualised revenue run-rate of $52–$57 million. The company's Clinical Solutions segment showed momentum, with clinical customers growing 25% in 2025. Alpha Teknova now supports over 70 therapies in clinical trials, including five in Phase II/III, and expects to begin supporting at least one commercial therapy soon, which could significantly boost volumes. The company emphasises small-batch GMP manufacturing and fast turnaround as key differentiators. Management said its dynamic capacity and new GMP facility can support growth up to $200 million with limited additional capital. Alpha Teknova ended the year with $21 million cash and a $5 million unused credit line.

Life Care
Mar 12th, 2025
Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

HOLLISTER, Calif., March 11, 2025 (GLOBE NEWSWIRE) - Alpha Teknova, Inc. ("Teknova") (Nasdaq: TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze(TM) product line, a cryopreservative and cell wash media system intended for use by customers who are developing next generation allogeneic cell therapies.

Recently Posted Jobs

Sign up to get curated job recommendations

teknova is Hiring for 4 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →